Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 4/20 | 0.45 |
| ▸ | DRD5 | P21918 | 4/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128540 | 0.93 | OGA (0.55) | OGAHPGDALDH1A1TP53LMNA | |
| SCHEMBL15131063 | 0.91 | OGA (0.56) | OGAHPGDALDH1A1TP53LMNA | |
| SCHEMBL5120634 | 0.89 | OGA (0.50) | OGAHPGDALDH1A1TP53LMNA | |
| SCHEMBL5120695 | 0.88 | ACHE (0.45) | ALDH1A1TSHRHSD17B10KDM4EMAPT | |
| SCHEMBL5132002 | 0.87 | OGA (0.48) | OGAHPGDALDH1A1TP53LMNA | |
| SCHEMBL5126941 | 0.86 | OGA (0.49) | OGAHPGDALDH1A1TP53LMNA | |
| SCHEMBL5131986 | 0.85 | KDM4E (0.47) | OGAALDH1A1TSHRHSD17B10FAAH | |
| SCHEMBL5128313 | 0.83 | OGA (0.55) | OGAHPGDALDH1A1LMNATSHR | |
| SCHEMBL5121371 | 0.81 | ACHE (0.46) | ALDH1A1TSHRHSD17B10FAAHKDM4E | |
| SCHEMBL5128220 | 0.79 | ACHE (0.42) | ALDH1A1TSHRHSD17B10FAAHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | claimed |
| WO-2005077903-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED TETRAHYDROISOQUINOLINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | MCHR1, MCHR2, MC1R | OGA 4569/4885HPGD 972/4885ALDH1A1 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.